companies / scorpiontx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
Scorpion Therapeutics was listed in Atlas Venture's portfolio, recorded 2026-09-30.
verified=2026-10-03 json
| total_raised | 150,000,000150.0M | ○ |
|---|---|---|
| founded | null | |
| hq | Boston MA | |
| industry | unknown | |
| stage | series-b+ |
Scorpion Therapeutics is a clinical-stage precision-oncology biotech designing mutant-selective small molecules for patients with specific cancer driver mutations. It targets PI3K-alpha-mutant breast, gynecological, and other solid tumors. Lilly acquired the lead program STX-478 for up to $2.5B in milestones in early 2025.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-07-01 | series-c | 150,000,000150.0M | null | ○ |
| investor | src |
|---|---|
| Lightspeed Venture Partners | ○ |
| Atlas Venture | ○ |
| fact | status | src |
|---|---|---|
| Series C, $150.0M | attributed | ○ |
| Investor Atlas Venture | sourced | WEB |
| existence | sourced | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-10-03provenance_existence: self-reported → sourced, WEB 2026-10-03 | provenance_existence | self-reported → sourced | WEB 2026-10-03 |
| 2026-09-30provenance_investor_atlas_venture: unknown → sourced, WEB 2026-09-30 | provenance_investor_atlas_venture | unknown → sourced | WEB 2026-09-30 |
| 2026-09-27latest_round: series-c, $150.0M, 2024-07-01, lead: lightspeed → series-c, $150.0M, 2024-07-01, lead: null, ○ 2026-05-07 | latest_round | series-c, $150.0M, 2024-07-01, lead: lightspeed → series-c, $150.0M, 2024-07-01, lead: null | ○ |
Records begin 2026-09-24. all_changes